双特异性抗体是含有两种特异性抗原结合位点的双功能抗体。我

们通过化学交联法将抗CD3单抗与曲妥珠单抗交联，获得了对肿瘤

细胞和淋巴细胞的双向识别作用的双特异抗体。此双特异性抗体

一方面通过CD3单抗识别HIM-IC细胞；另一方面，通过曲妥珠单抗识

别肿瘤表面HER2受体。

在HIM-IC细胞体外诱导、培养的＊后阶段加入该双特异抗体，双特

异抗体即通过抗CD3抗体结合到HIM-IC细胞表面，HIM-IC细胞回输到体内

后，其表面的双特异抗体将HIM-IC细胞靶向募集到肿瘤细胞表面，从

而提高HIM-IC细胞对肿瘤细胞的识别和杀伤活性。

技术特点

l   制备技术相对简单；

l   利用抗体-抗原的强大亲和力，大大提高HIM-IC细胞对肿瘤细胞的

识别和杀伤机会。

Bispecific antibody / DC-CIK technology

A bispecific antibody is a bifunctional antibody that contains two specific antigen 

binding sites. We cross-linked anti-CD3 monoclonal antibody with trastuzumab

 by chemical cross-linking, and obtained bi-specific antibodies for bi-directional 

recognition of tumor cells and lymphocytes. This bispecific antibody recognizes

 CIK cells via CD3 target and recognizes tumor cells via HER2 receptor.

In the final stage of DC-CIK cells culturing, the bispecific antibody was added and

 binds to the surface of CIK cells through anti-CD3 antibody. After transfusion, the 

 cells were recruited to tumor cells through bispecific antibody, thereby enhancing

 the recognition and killing activity of CIK cells to tumor cells.

Technical features

1.   The preparation technique is relatively simple

2.   The strong affinity of antibody to antigen greatly improves the DC-CIK cells on

 tumorcell recognition and killing opportunities